TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19364964
Drug: Intensive dose-dense
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dose-dense (IDD) chemotherapy
Study: 17587070
Drug: Amoxicillin (AMOX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMOX) 1 g twice daily for 100 days
Study: 22215943
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2000 IU/d) with Peg‐α‐2b interferon (1.5 μg/kg per week) plus ribavirin (1000‐1200 mg/d)
Study: 24237300
Drug: Interferon-alpha lozenge
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha lozenge 500 IU/day
Study: 27215298
Drug: Free sachet
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free sachet water vouchers (15 L/week/child) plus education
Study: 25596108
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy to the rectum
Study: 28973220
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment group
Study: 26535969
Drug: Extended-release hydrocodone
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release hydrocodone (20-300mg) every 12 hours
Study: 20673731
Drug: Closed reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed reduction and functional treatment
Study: 12559267
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel injection
Study: 9424404
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite allergen (HDM) extract inhalation challenge in atopic asthmatics (AA)
Study: 9424404
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite allergen (HDM) extract inhalation challenge in atopic non-asthmatics (AN)
Study: 8243376
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) as add-on treatment
Study: 9081682
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet with fish oil capsules (6 or 12 capsules daily)
Study: 8256107
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg weekly chloroquine (n = 156)
Study: 24632279
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) treatment in patients without DM and type B2/C lesions
Study: 9101306
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (ceronapril or delapril)
Study: 23503379
Drug: Genetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic therapy combined with traditional treatment (conservative means) in 39 patients.
Study: 22375408
Drug: Respiratory exercises
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory exercises increases Chinese medicine
Study: 19909605
Drug: Piroxicam 10
Normalized name: piroxicam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 10 mg oral dose 1-2 hours before embryo transfer
Study: 29145890
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg metolazone single dose
Study: 24806159
Drug: Letermovir 120
Normalized name: letermovir 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir 120 mg per day
Study: 16544963
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg bd acetazolamide
Study: 22449319
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus Roux‐en‐Y gastric bypass
Study: 12932243
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1% pyrithione zinc shampoo and 5% minoxidil topical solution
Study: 22449319
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus sleeve gastrectomy
Study: 20861810
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of radiation therapy
Study: 31952661
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy
Study: 19583558
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment
Study: 19287303
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (300 microg twice weekly)
Study: 29389170
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg/day
Study: 12537629
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment
Study: 20031704
Drug: Angiography-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiography-directed therapy
Study: 15632861
Drug: Loratidine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratidine 10 mg daily for 7 days (group B)
Study: 15632861
Drug: Loratidine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratidine 10 mg daily for 7 days (group A)
Study: 15205487
Drug: Alpha tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha tocopherol (50 mg daily)
Study: 15205487
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (20 mg daily)
Study: 24935294
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil 2 g/d plus standard‐dose cyclosporine
Study: 27189087
Drug: Tian Jiu
Normalized name: Tian Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tian Jiu therapy (TJ)
Study: 27801753
Drug: Lower enteral
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower enteral protein intake (0.4 g/100 mL expressed breast milk)
Study: 27801753
Drug: Higher enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher enteral protein intake (1 g/100 mL expressed breast milk)
Study: 10992369
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination
Study: 2186980
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at 10 pm
Study: 2877383
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone treatment
Study: 18430965
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 300 mg weekly for 16 weeks
Study: 15290000
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg BID
Study: 14505898
Drug: DTPw vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw vaccine
Study: 28323965
Drug: C-terminal peptide-modified
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C-terminal peptide-modified hGH (MOD-4023) at doses of 0.25, 0.48, or 0.66 mg/kg/wk
Study: 28233459
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily plus vitamin D 60,000 units once weekly
Study: 26597741
Drug: Aspirin 60
Normalized name: aspirin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 60 mg/d
Study: 31347430
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 to 200 mg (aspirin group)
Study: 31347430
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 to 200 mg plus cilostazol 200 mg (dual group)
Study: 7936257
Drug: Protocol for
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol for treatment of acute stroke
Study: 1349485
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nitrendipine
Study: 1349485
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bisoprolol
Study: 17089419
Drug: Higher weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Higher weekly contact hours
Study: 15209772
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin
Study: 16931867
Drug: Glucose+fructose solution
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose+fructose solution
Study: 1020902
Drug: 5 000
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 000 units of heparin preoperatively and every 12 hours following the operation
Study: 31630117
Drug: Programmed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed treatment group
Study: 27469171
Drug: Tapered interference
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapered interference fit (TIF) implants
Study: 1691243
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies targeting different viral replicative sites
Study: 25582816
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (levofloxacin 500 mg daily and ibuprofen 200 mg twice a day for 6 weeks)
Study: 28043731
Drug: Acetazolamide (250mg)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (250mg) and Hydrochlorothiazide (50mg) daily
Study: 28043731
Drug: Furosemide (40mg)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (40mg) and Hydrochlorothiazide (50mg) daily
Study: 22292366
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (WM group)
Study: 7530680
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with bleomycin, etoposide, and cisplatin
Study: 7957521
Drug: Oral colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral colchicine 1 mg (healthy volunteers)
Study: 7957521
Drug: Oral colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral colchicine 1 mg (elderly subjects)
Study: 8523876
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin protocol
Study: 27065001
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg once daily (up-titrated to 50 mg/day after 4 weeks)
Study: 10439688
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (n = 80)
Study: 22095569
Drug: Mass azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass azithromycin distributions (3 annual treatments)
Study: 18847313
Drug: G-CSF alone
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF alone
Study: 6364329
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg metronidazole as a single dose on the first and third days
Study: 11030499
Drug: Stretching intervention
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching intervention (30 minutes of daily stretching into dorsiflexion with a torque of 7.5 N x m for 4 weeks)
Study: 14713918
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg daily and zafirlukast 20 mg twice a day
Study: 9209776
Drug: Sumatriptan 5
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 5 mg
Study: 2182350
Drug: Daily-wear hard
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-wear hard (DWH) PMMA contact lens
Study: 43950
Drug: 40 or
Normalized name: Azor 5/40 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 or 100 mg betadrenol
Study: 17174226
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (60 mL, fresh and deep-fried)
Study: 25381189
Drug: Reiki therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reiki therapy
Study: 7872895
Drug: Cisplatin followed
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin followed by 120-hr continuous 5-FU infusion (Group A)
Study: 16600443
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine (104.7, 105.2, or 106.1 ffu)
Study: 10348579
Drug: Adjunctive abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive abciximab
Study: 1359666
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid
Study: 24837064
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment Control
Study: 29733403
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation (60 mg iron and 2.8 mg folic acid)
Study: 12453954
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg
Study: 24602553
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT)
Study: 7768272
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg glyburide
Study: 27344831
Drug: Point application
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point application treatment using herbal plaster on acupoints Dingchuan (EX-B1), Feishu (BL 13), Gaohuang (BL 43), and Danzhong (CV 17) for 2 to 4 hours on the first day of each of the three periods of the hot season.
Study: 15782623
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b at 6MIUs.c./three-times-weekly (group A)
Study: 7954244
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (48.0 Gy or 54.4 Gy)
Study: 16682611
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN (5 mg)
Study: 26874557
Drug: Clonidine 300
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 300 μg oral premedication administered 90 minutes before surgery
Study: 7378674
Drug: Iotroxamide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iotroxamide infusion
Study: 9695133
Drug: Lupron injections
Normalized name: Lupron Injectable Product
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron injections (GnRH agonist) followed by transdermal estradiol (Patch)
Study: 30241510
Drug: CYD‐TDV accelerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD‐TDV accelerated schedule with YF co‐administered
Study: 10509552
Drug: Fosinopril and
Normalized name: fosinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril and HCTZ with ibuprofen
Study: 7815656
Drug: Zidovudine at
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine at 200 mg (later 100 mg) every 4 hours
Study: 1901808
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ponalrestat
Study: 26890736
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg twice a day
Study: 26890736
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg/day
Study: 16084880
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG (200 IU/day) alone after ovarian priming with recombinant FSH/hMG (group B)
Study: 28950424
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration
Study: 29588972
Drug: Lacosamide 600
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide 600 mg/day
Study: 19687343
Drug: Atorvastatin (ATOR)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATOR) 80 mg/d for 12 weeks
Study: 29050507
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance strength training (twice a week for 12 weeks, load of 50% and 70% of one repetition maximum)
Study: 27893326
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine (platinum therapy)
Study: 10443658
Drug: Insulin analog
Normalized name: insulin analog, glargine 300 UNT Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin analog (Lispro)
Study: 10443658
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (Velosuline)
Study: 23415779
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A 0.05% emulsion twice daily for 3 months postoperatively
Study: 31462489
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual alone
Study: 31462489
Drug: six-session VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: six-session VR cognitive treatment added to treatment as usual
Study: 15231854
Drug: Whisky consumption
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whisky consumption (40 g of alcohol daily for 17 days)
Study: 26537944
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g pure whey protein isolate (H)
Study: 3520160
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of glucose, insulin, and potassium
Study: 11703474
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 6 mg
Study: 23881958
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus extended-release niacin (ERN) (1500-2000 mg/d)
Study: 17720079
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of triamcinolone acetonide
Study: 19301232
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 50 (50% lispro, 50% insulin lispro protamine suspension) pre-breakfast and lispro mix 25 (25% lispro, 75% insulin lispro protamine suspension)
Study: 20555293
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel
Study: 20345708
Drug: Blocking antibody
Normalized name: Blocking antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking antibody against PAI-1
Study: 8739857
Drug: anti-CD4 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CD4 monoclonal antibody/prednisolone
Study: 29570853
Drug: Levodopa-carbidopa intestinal
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa intestinal gel
Study: 18588355
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg once daily
Study: 18547293
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg morphine in 10 ml saline